Oujiang Laboratory, approved by the Zhejiang Provincial Government and jointly established by the Wenzhou Municipal People's Government and the Zhejiang Provincial Department of Science and Technology, was officially inaugurated in May 2021. The laboratory focuses on three main research directions: tissues and organs regeneration and remodeling, brain diseases and cognitive rehabilitation, and eye diseases and visual function rehabilitation. It carries out scientific research and technological innovation , striving to build a major scientific innovation platform in regenerative medicine, eye, and brain health that is "domestically leading and internationally first-class" .

The laboratory boasts nearly 250,000 square meters of research space. It has attracted  50 high-level research teams, bringing together over 800 researchers, including 9 academicians, 29 national-level talents, and 35 provincial-level talents. It has undertaken 138 national, ministerial, and provincial-level research projects, with research funding support exceeding 120 million RMB. The lab has published over 1,000 high-quality papers in international academic journals such as《Nature》and《Cell》, including more than 300 highly-cited papers ranking in the global top 10%. It has established major research infrastructures including  Core Facilities Laboratory Animal Center and The Biomedical Big Data Intelligent Computing Center.all of which are open for shared use . The laboratory has successfully obtained approval for national-level postdoctoral research workstations, provincial foreign expert workstations, and provincial-level science-education integration pilot units. the lab took the lead among provincial laboratories in exploring the "funding-to-equity" model to support the industrialization of research outcomes, it has nurtured 18 companies .

The laboratory's findings on the structure and function of Fibroblast Growth Factor (FGF) were published in《Nature》. Simultaneously, the laboratory has achieved significant breakthroughs in areas including the early diagnosis, prevention, and treatment of Alzheimer's disease, research on the pathogenic mechanisms and precise diagnosis/treatment of mental illnesses for drug development, eye-brain interaction mechanisms, myopia intervention, and drug development for fundus vascular diseases . The laboratory's project focusing on a "novel precise target for the tumor immune microenvironment" has entered the CRO stage, having received 15 million RMB in social capital investment and reaching a post-investment valuation of 300 million RMB